Article
St. Louis, MO-TLC Vision Corp. has made an equity investment in Vascular Sciences Corp. to establish OccuLogix, a 50/50 joint venture to commercialize Vascular Sciences' Rheopheresis blood filtration process for treating age-related macular degeneration (AMD).